HIV and the ART of Prevention

Slides:

Advertisements

Similar presentations

9th Advanced HIV Course Aix-en-Provence 2011 Role of ARV as Prevention Martin Fisher Brighton and Sussex University Hospitals, UK.

Advertisements

Cristin Muecke, RMOH Nick Scott, ED AIDS NB.  Why HIV testing remains important  Treatment as prevention  Discuss advantages/disadvantages of various.

Dr. Carol Odula (Obs./Gyn.) May 7 th 2013 Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection.

STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.

Integration with ART for HIV+ Heterosexual men Risk of Resistance MSM High-risk women Young MSM of color Transgender women Long-term safety Provider attitudes.

Preparing for pre-exposure prophylaxis (PrEP) to prevent HIV infection James Wilton Project Coordinator Biomedical Science of HIV Prevention

HIV in Texas: The Ways Forward Ann Robbins Manager of HIV/STD Prevention and Care Department of State Health Services.

TasP is not enough Stipulated that TasP is effective in reducing infectiousness of the treated person – But much more is required. TasP requires effective.

HIV Prophylaxis: Following Occupational and Non-Occupational Exposure Nanik (Nayri) Hatsakorzian Pharm.D./MPH candidate 2014 Touro University, College.

Potential role of PEP, PrEP and ART for HIV Prevention among Men who have Sex with Men Frits van Griensven, PhD, MPH Division of HIV/AIDS Prevention US.

Incorporating HIV Prevention into the Medical Care of Persons Living with HIV Ask ∙ Screen ∙ Intervene Developed by: The National Network of STD/HIV Prevention.

Are people living with HIV less likely to pass HIV to others if they are on treatment? Exploring the use of treatment as prevention James Wilton Project.

The Strategic Use of ARVs | IAC Satellite, July 22, |1 | Strategic Use of Antiretroviral Drugs WHO Perspective for Future Guidelines Chair of WHO.

ADAP Solutions for the future Glen Pietrandoni, R.Ph., AAHIVP, Sr Director, Virology Adam Reno, Sr. Strategic Account Manager, State Governments ©2013.

JORDAN E. LAKE, MD, MSC AAHU SEPTEMBER 2014 Prevention for Positives.

What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,

Implementation of HIV Treatment as Prevention in China Yan Zhao MD National Center for AIDS/STD Control & Prevention Chinese Center for Disease Control.

AIDS 2012 Where are we, and where are we going? Mitchell Warren Executive Director, AVAC August 15, 2012.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

November 5, 2014 Matthew Tuck, MD Hospitalist, Veterans Affairs Medical Center Assistant Professor of Medicine, George Washington University.

ART: When to Start? – Case Discussion Roy M. Gulick, MD, MPH Professor of Medicine Chief, Division of Infectious Diseases Weill Medical College of Cornell.

JORDAN E. LAKE, MD, MSC AAHU AUGUST 2015 Prevention for Positives.

PRECONCEPTION COUNSELING AND CARE FOR HIV-INFECTED WOMEN OF CHILDBEARING AGE.

The HIV Care Continuum: A Tool for Driving Systematic Change to Support Better Engagement in Care Jeffrey S. Crowley Distinguished Scholar/ Program Director.

PrEP Update: The science, new tools, and next steps Dawn K. Smith MD, MS, MPH Division of HIV/AIDS Prevention, CDC “The findings and conclusions in this.

N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Pre-exposure Prophylaxis for HIV Prevention Efficacy and the importance of adherence Joanne Stekler,

New ARV-based prevention tools how the research is happening how we need to be involved Anna Forbes, MSS Consultant, HIV and women’s health HIV Research.

Effective HIV & SRH Responses among Key Populations Module 2: The Comprehensive Package of Programmes and Services.

Washington D.C., USA, July 2012www.aids2012.org Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples: a systematic.

The Continuum of Participation in Research From HIV Prevention to Care: Seven Years of the iPrEx Trial Public Engagement with HIV Science.

HIV and Women Collaborating Across Borders to Advance the Health of Women IAS 2012 Gina M. Brown, M.D. July 22, 2012.

N ORTHWEST AIDS E DUCATION AND T RAINING C ENTER HIV Prevention in Clinical Care Settings Jeanne Marrazzo, MD, MPH Professor, Division of Allergy and Infectious.

The tipping point: When do placebos become unethical? Bridget Haire.

PrEP for HIV Prevention

Module 4 (e) Pregnancy and Breast Feeding

Preexposure Prophylaxis (PreP) for the Prevention of HIV

Module 4 (c) Stopping PrEP

Adherence and Acceptability for PrEP formulations

MTN-025 (HOPE Study) Community Education Presentation

PrEP: A Case-by-Case Approach

Managing Women Living With HIV Infection

PrEP introduction for Adolescent Girls and Young Women

Program Goals Overview of HIV Epidemic HIV and Communities of Color.

The Possibilities of PrEP: Introduction

PrEP Effectiveness. Preexposure Prophylaxis Translating the Clinical Trials Into Clinical Practice.

Stopping the Epidemic HIV Prevention Today

Content Vocabulary abstinence monogamous safer-sex strategies

Setting the Stage for PrEP Where are we now, and where should we go?

PrEP in Women: Unique Considerations and Strategies

Translating Emerging HIV Data Into Clinical Practice

Agenda. Agenda HIV in the United States HIV in the United States (cont)

Is it Time for a Paradigm Change in HIV Management?

Initiating Pre-exposure Prophylaxis The PrEP Checklist

HPTN 082 Uptake and adherence to daily oral PrEP as a primary prevention strategy for young African women: A Vanguard Study.

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Rectal Gels for PrEP Are They an Option?

Tools to Address Adherence Issues in Patients With SIHD

100 Partners PrEP[5] Efficacy 75% Adherence 81% 80

PrEP Ongoing Care.

CAD/PAD in Primary Care

Dianne Rausch, Ph.D. Director, Division of AIDS Research

Medical Management of HIV Among Transgender Adults

Analytic framework illustrating exposure to preventive measures that reduce the risk of transmission between HIV-serodiscordant sex partners. Analytic.

Lesson 3: Treatment as Prevention

U=U Guidance for Implementation in Clinical Settings

Undetectable = Untransmittable

Bob Holtkamp, Director of Prevention & Outreach

Presentation transcript:

HIV and the ART of Prevention

Estimated New HIV Infections By Transmission Category 2002 vs 2011

Estimated New HIV Infections By Transmission Category 2002 vs 2011 (cont)

SAFE A Serostatus Approach to Fighting the Epidemic

SAFE 5 Steps for HIV Prevention

HIV Continuum of Care

Barriers to Implementing SAFE

Preventing Transmission Requires A Multifaceted Strategy

High-impact Prevention Approach to Reducing New HIV Infections

HIV Prevention Begins With Knowledge of Serostatus

PrEP

iPrEx Study Oral TDF/FTC Once Daily Effective in Preventing HIV Infection (N = 2499)

Partners PrEP Safe and Effective for Serodiscordant Heterosexual Couples

Studies of PrEP Using Antiretrovirals to Prevent HIV Infection

PrEP Guidance

PrEP Guidance (cont)

HPTN 052 Study Early ART Reduces HIV-1 Transmission in Serodiscordant Couples From The Infected to the Uninfected Partner

Effective ART Reduces the HIV Transmission Risk of Condomless Sex From Efficacy to Effectiveness

Overcoming Barriers to Use and Effectiveness of PrEP

PREP US Demo Project Baseline Risk Behaviors and PrEP Acceptance

Dose-response Relationship Between Adherence and Efficacy of PrEP

Adherence to PrEP Prescription + Counseling

iPrEx OLE Study Perfect Adherence Not Necessary for Effective PrEP

CDC and USPSTF Guideline Evolution for HIV Testing in the Medical Setting

Identifying Patient Candidates for PrEP

How Many Potential PrEP Users Are There in the United States?

PrEP Who and Where?

Before PrEP: Assessing High-risk Behaviors You Have to Ask

PrEP Is More Than a Prescription

Adherence Strategies Customized for Specific Populations

Summary HIV Transmission Prevention Strategies

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)